The impact of molecular targets in cancer drug development: major hurdles and future strategies

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

(2012) Kristin Bergethon et al.   JOURNAL OF CLINICAL ONCOLOGY

Moving molecular targeted drug therapy towards personalized medicine: Issues related to clinical trial design

(2012) Jaap Verweij et al.   Molecular Oncology

Clonal evolution in cancer

(2012) Mel Greaves et al.   NATURE

Industry perspectives on personalized medicine

(2012) Rachael Zuckerman et al.   NATURE REVIEWS DRUG DISCOVERY

2011 FDA drug approvals

(2012) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical trials for predictive medicine

(2012) Richard Simon   STATISTICS IN MEDICINE

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Is there still room for large registrative trials in unselected cancer patients? The case of anti-epidermal growth factor receptor antibodies in advanced non-small-cell lung cancer

(2011) Massimo Di Maio   EXPERT OPINION ON BIOLOGICAL THERAPY

Aptamers for allosteric regulation

(2011) Jan L Vinkenborg et al.   Nature Chemical Biology

Harnessing synthetic lethal interactions in anticancer drug discovery

(2011) Denise A. Chan et al.   NATURE REVIEWS DRUG DISCOVERY

How were new medicines discovered?

(2011) David C. Swinney et al.   NATURE REVIEWS DRUG DISCOVERY

Advances in the preclinical testing of cancer therapeutic hypotheses

(2011) Giordano Caponigro et al.   NATURE REVIEWS DRUG DISCOVERY

Clinical trials for predictive medicine: new challenges and paradigms

(2010) Richard Simon   Clinical Trials

Targeting of Leukemia-Initiating Cells to Develop Curative Drug Therapies: Straightforward but Nontrivial Concept

(2010) P. Valent   CURRENT CANCER DRUG TARGETS

Personalized medicine in oncology: the future is now

(2010) Richard L. Schilsky   NATURE REVIEWS DRUG DISCOVERY

Anticancer drug development: the grand challenges

(2010) William N. Hait   NATURE REVIEWS DRUG DISCOVERY

Targeted cancer therapies

(2010) Saurabh Aggarwal   NATURE REVIEWS DRUG DISCOVERY

Impact of molecular targets in cancer drug development: historical influence and future perspectives

(2010) Edgar Selzer   Expert Review of Clinical Pharmacology

American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

(2009) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question

(2009) T. Fojo et al.   JNCI-Journal of the National Cancer Institute

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

(2009) Robert Pirker et al.   LANCET

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

(2009) James A Bonner et al.   LANCET ONCOLOGY

Imatinib and beyond—exploring the full potential of targeted therapy for CML

(2009) Alfonso Quintás-Cardama et al.   Nature Reviews Clinical Oncology

The intrinsic dynamics of enzymes plays a dominant role in determining the structural changes induced upon inhibitor binding

(2009) A. Bakan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Update on Anti-EGFR Targeted Therapy

(2009) Daniel Chua et al.   Journal of Oncology

Molecular Subtypes in Breast Cancer Evaluation and Management: Divide and Conquer

(2008) Jeffrey Peppercorn et al.   CANCER INVESTIGATION

Oncogene Addiction

(2008) I. B. Weinstein et al.   CANCER RESEARCH

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY

Protein crystallization: from purified protein to diffraction-quality crystal

(2008) Naomi E Chayen et al.   NATURE METHODS

Leader of the pack: gene mapping in dogs and other model organisms

(2008) Elinor K. Karlsson et al.   NATURE REVIEWS GENETICS